spacer
home > ebr > spring 2018 > getting ahead
PUBLICATIONS
European Biopharmaceutical Review

Getting Ahead

Migraine is not a new or a rare disease: references to migrainelike conditions can be found as far back as Ancient Egypt, and it has been recognised by the WHO as one of the top 10 causes of years lost to disability worldwide (1-2). Despite this, migraine patients in need of a preventive option are likely to be prescribed a medication that has been developed for another condition such as epilepsy or depression, rather than something that was designed with migraine in mind. However, there is hope that this will soon change.

Pathophysiology of Migraine

The understanding of the pathophysiology of migraine has advanced hugely over the past two decades. While in the past theories of migraine focused on the vascular system, research has moved away from this towards a neuronal theory of migraine (3). However, the role of blood vessels and vasodilation is still not entirely understood.

Migraine is a complex neurological disease of the central nervous system (CNS), with several structures and brain areas implicated in its genesis. A key focus area has been the trigeminovascular system. This has connections with other key brain areas with axons reaching as far as the meninges. Activation of this system is thought to be a crucial step in a chain of events leading to migraine pain.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Professor Dr Uwe Reuter is a neurologist and partner in the headache programme at Charité Universitätsmedizin, Berlin. After finishing his residency training in Berlin, he went to Harvard Medical School for a post-doctorate fellowship as a scholar for three years. During his time in Boston, Uwe focused on basic research in primary headaches and migraine aura and published several peer-reviewed publications in high impact journals. Ever since, he has had a strong interest in basic and clinical headache research. Uwe is a member of several national and international headache organisations and currently serves as board member of the European Headache Federation.
spacer
Professor Dr Uwe Reuter
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

ChemAxon and AWS simplify getting scientists moving on the cloud

Listen to a talk by Paul Underwood of AWS introducing Biotech Blueprint, a cloud based solution for cheminformatics. The technology for novel compound registration is provided by ChemAxon.
More info >>

White Papers

Tabletability, Compactability, and Compressibilty: What’s the Difference?

Natoli Engineering Company, Inc.

To patients and consumers, tablets are a simple and convenient dosage form. But the science behind compressing a block of particles or granules into a single tablet can be complicated. That’s where common compression studies can help. This article explains how to develop tabletability, compactibility, and compressibility profiles.
More info >>

 
Industry Events

SMI Immuno-Oncology Conference

25-27 September 2018, Copthorne Tara Hotel, London, UK

Immuno-Oncology is a fast-paced field with massive potential to deliver successful and durable cancer therapies, and SMi's Immuno-Oncology Conference will focus on a few key areas of the field with a representation of the whole industry under each area. These areas will be drawn together to look towards the future of Immuno-oncology and how the field can progress.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement